The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER−/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute

Table 2

The clinicopathological characteristics of the four ER/PR profiles of included patients.

	ER+/RP+ (58.4%)	ER+/RP− (7.6%)	ER−/RP− (14.2%)	ER−/RP+ (8.1%)	value
Characteristics
Age groups at diagnosis
≤50 years	369 (55.4%)	36 (41%)	77 (49.7%)	48 (51.1%)
>50 years	297 (44.6%)	52 (60%)	78 (50.3%)	46 (48.9%)
Grade
1	78 (11.7%)	7 (8%)	2 (1.3%)	10 (10.6%)
2	368 (55.3%)	41 (46.6%)	55 (33.5%)	32 (34%)
3	165 (24.8%)	31 (35.2%)	87 (56.1%)	47 (50%)
NA	(8.2%)	10.2%	9%	5.4%
Tumor size
≤2 cm	185 (36.3%)	22 (33.8%)	30 (24.2%)	18 (28.6%)
>2 cm	305 (59.8%)	42 (64.6%)	89 (71.8%)	43 (68.3%)
NA	3.9%	1.6%	4%	3%
Lymph node status
Positive	301 (45%)	38 (43%)	57 (40.2%)	29 (31.2%)
Negative	142 (21.24%)	23 (26.1%)	53 (36.8%)	23 (24.5%)
NA	66.2%	31%	23%	44%
PtT	149 (22.1%)	17 (19.3%)	29 (17.7%)	15 (16%)
T2	243 (36.1%)	32 (36.4%)	76 (46.3%)	27 (28.7%)
T3	33 (5%)	8 (9.1%)	9 (5.5%)	7 (7.4%)
T4	27 (4%)	5 (5.7%)	5 (3%)	7 (7.4%)
NA	32%	29.5%	27.5%	40.5%
HER2 status
Negative	467 (20.7%)	48 (38.6%)	97 (31.6%)	54 (34%)
Positive	138 (70.6%)	33 (53.4%)	49 (62%)	33 (59.6%)
NA	8.7%	8%	6.4%	6.4%
KI67
≤20%	155 (28.6%)	16 (29.1%)	19 (17.9%)	11 (16%)
>20%	387 (72%)	39 (70.9%)	87 (82.1%)	65 (84%)

NA: not available.